Remibrutinib
Remibrutinib, is a potent and orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM. Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood[1]. Remibrutinib has the potential for Chronic urticaria (CU) treatment[2].
Product Specifications
CAS Number
1787294-07-8
Product Name Alternative
LOU064
UNSPSC
12352005
Hazard Statement
H317, H334
Target
Btk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/remibrutinib.html
Purity
99.76
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC(F)=CC(C2=NC=NC(N)=C2OCCN(C)C(C=C)=O)=C1C)C3=CC=C(C4CC4)C=C3F
Molecular Formula
C27H27F2N5O3
Molecular Weight
507.53
Precautions
H317, H334
References & Citations
[1]Daniela Angst, et al. Novel amino pyrimidine derivatives. Patent WO2015079417A1.|[2]Kolkhir P, et al. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2019 Aug 23.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
